产品说明书

Dronedarone Hydrochloride

Print
Chemical Structure| 141625-93-6 同义名 : 决奈达隆盐酸盐 ;Dronedarone (hydrochloride);SR33589;Dronedarone HCl
CAS号 : 141625-93-6
货号 : A127630
分子式 : C31H45ClN2O5S
纯度 : 95%
分子量 : 593.22
MDL号 : MFCD00914940
存储条件:

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 25 mg/mL(42.14 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
靶点
  • Calcium Channel

  • Potassium Channel

  • Sodium Channel

描述 Dronedarone hHydrochloride, is a non-iodinated amiodarone derivative that inhibits Na+, K+ and Ca2+ currents. It is a potent inhibitor of the acetylcholine-activated K+ current from atrial and sinoatrial nodal tissue, and inhibits the rapid delayed rectifier more potently than slow and inward rectifier K+ currents and inhibits L-type calcium current. Dronedarone is an antagonist at alpha- and beta-adrenoceptors and unlike amiodarone, has little effect at thyroid receptors[3]. Intravenous administration of dronedarone hydrochloride in doses of 0.3 and 3 mg/kg over 30s attained the peak plasma concentrations of 61 and 1248 ng/mL, respectively, reflecting sub- to supra-therapeutic ones. The low dose decreased the left ventricular contraction and mean blood pressure, which were enhanced at the high dose. The high dose also decreased the heart rate and cardiac output, but increased the total peripheral resistance and left ventricular end-diastolic pressure, showing its potent cardiodepressive profile. Dronedarone significantly prolonged the T(peak)-T(end) in a dose-related manner with a tendency to prolong the terminal repolarization period and J-Tpeakc, indicating considerable risk to induce torsade de pointes[4]. Improved oral bioavailability of dronedarone could be provided by an optimized proliposomal formulation with enhanced solubility, permeability, and oral absorption[5]. In guinea pig ventricular myocytes, dronedarone exhibited a state-dependent inhibition of the fast Na(+) channel current with an IC(50) of 0.7 ± 0.1 μM, when the holding potential (V (hold)) was -80 mV. The maximal block at the highest concentration used was 77 ± 8%. In contrast, when V (hold) was -100 mV, inhibition with 10 μM dronedarone was only 9 ± 3% (n = 7). Dronedarone blocked Ca(2+) currents elicited by rectangular pulses at V (hold) = -40 mV with an IC(50) value of 0.4 ± 0.1 μM (maximal block by 10 μM dronedarone, 80 ± 6%), whereas at V (hold) = -80 mV, 10 μM dronedarone blocked only 20 ± 6% (n = 4) of the current. Inhibition of fast Na+ and Ca2+ channels by dronedarone depends on the cell’s resting membrane potential (state-dependent block) favouring an atrialselective mode of action. Besides fast Na+ and Ca2+ channels, dronedarone also inhibits HCN4 currents. This might contribute to the clinically observed reduction in heart rate seen in patients in sinus rhythm after dronedarone treatment[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.69mL

0.34mL

0.17mL

8.43mL

1.69mL

0.84mL

16.86mL

3.37mL

1.69mL

参考文献

[1]VarroA, Takacs J, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol. 2001 Jul;133(5):625-34.

[2]Altomare C, Barbuti A, et al. Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. Br J Pharmacol. 2000 Jul;130(6):1315-20.

[3]Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs. 2004; 13(4):415‐426

[4]Motokawa Y, Nakamura Y, Hagiwara-Nagasawa M, et al. In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic Drugs. Cardiovasc Toxicol. 2018;18(3):242‐251

[5]Kovvasu SP, Kunamaneni P, Yeung S, Rueda J, Betageri GV. Formulation of Dronedarone Hydrochloride-Loaded Proliposomes: In Vitro and In Vivo Evaluation Using Caco-2 and Rat Model. AAPS PharmSciTech. 2019; 20(6):226. Published 2019 Jun 18

[6]Bogdan R, Goegelein H, Ruetten H. Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn Schmiedebergs Arch Pharmacol. 2011; 383(4):347‐356